Cargando…
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials
PURPOSE: Dose-limiting neuropathy is a major adverse event associated with most of the microtubule-stabilizing agent-based chemotherapy regimens. Ixabepilone, a semisynthetic analogue of the natural epothilone B, has activity against a wide range of tumor types. Peripheral neuropathy (PN), associate...
Autores principales: | Vahdat, Linda T., Thomas, Eva S., Roché, Henri H., Hortobagyi, Gabriel N., Sparano, Joseph A., Yelle, Louise, Fornier, Monica N., Martín, Miguel, Bunnell, Craig A., Mukhopadhyay, Pralay, Peck, Ronald A., Perez, Edith A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461204/ https://www.ncbi.nlm.nih.gov/pubmed/22382588 http://dx.doi.org/10.1007/s00520-012-1384-0 |
Ejemplares similares
-
Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy
por: Vahdat, Linda T., et al.
Publicado: (2013) -
Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients
por: Ebenezer, Gigi J, et al.
Publicado: (2014) -
A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy
por: Kim, Yeul Hong, et al.
Publicado: (2012) -
Profile and potential of ixabepilone in the treatment of pancreatic cancer
por: Smaglo, Brandon G, et al.
Publicado: (2014) -
Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
por: Cristofanilli, Massimo
Publicado: (2012)